What is Opus Genetics's revenue?

Opus Genetics (IRD) generated $12.0M in revenue over the trailing twelve months, down 12.2% year over year.

Is Opus Genetics profitable?

Opus Genetics is not currently profitable: it reported a net loss of $106.9M over the trailing twelve months, a -892.4% net margin.

What is Opus Genetics's earnings per share?

Opus Genetics's diluted EPS over the trailing twelve months is $-1.33.

Where does Opus Genetics's income statement data come from?

Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Opus Genetics IRD Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$11.98M-15.6%	$14.2M-3.0%	$14.63M-5.1%	$15.42M+13.0%	$13.65M+24.2%
Research and development	——	——	——	——	——
General and administrative	$21.58M-1.8%	$21.98M-9.9%	$24.39M+9.4%	$22.3M+12.1%	$19.89M+9.2%
Compensation and benefits	$3.95M+16.2%	$3.4M-0.6%	$3.42M+1.2%	$3.38M+2.7%	$3.29M-2.1%
Other operating expenses	9,249,400,000%+222,200,000%	9,027,200,000%-2,027,100,000%	11,054,300,000%-48,600,000%	11,102,900,000%+234,800,000%	10,868,100,000%+488,000,000%
Total operating expenses	$55.02M+4.2%	$52.8M-33.8%	$79.81M-0.6%	$80.29M+3.0%	$77.95M+6.7%
Operating income	-$43.03M-11.5%	-$38.6M+40.8%	-$65.18M-0.5%	-$64.87M-0.9%	-$64.3M-3.6%
Operating margin	-359.1%-87.2pp	-271.9%+173pp	-445.4%-24.7pp	-420.7%+50.3pp	-471%+93.7pp
Interest expense	$198K+53.5%	$129K+89.7%	$68K—	$0—	$0—
Other income (expense), net	$2.53M+27.2%	$1.99M-51.6%	$4.11M-0.8%	$4.14M-0.7%	$4.17M-6.7%
Net investment gains (losses)	-$65.68M-470%	-$11.52M-101%	-$5.73M-251%	$3.79M+31.9%	$2.88M+3,896%
Income before income taxes	-$106.93M-116%	-$49.59M+27.3%	-$68.2M-17.0%	-$58.28M+0.6%	-$58.62M-1.9%
Income tax expense	$0—	$0—	$0—	$0—	$0—
Net income	-$106.93M-116%	-$49.59M+27.3%	-$68.2M-17.0%	-$58.28M+0.6%	-$58.62M-1.9%
Net margin	-892.4%-543pp	-349.3%+117pp	-466.1%-88.2pp	-377.9%+51.5pp	-429.4%+94.0pp
Diluted earnings per share	-$1.33-62.2%	-$0.82+56.4%	-$1.88+2.1%	-$1.92+8.6%	-$2.10+2.3%
Basic earnings per share	-$1.33-62.2%	-$0.82+56.4%	-$1.88+2.1%	-$1.92+8.6%	-$2.10+2.3%
Weighted-average shares, diluted	283.1M+23.0%	230.1M+18.2%	194.6M+29.6%	150.1M+33.4%	112.6M+9.1%
Weighted-average shares, basic	283.1M+23.0%	230.1M+18.2%	194.6M+29.6%	150.1M+33.4%	112.6M+9.1%
Adjustments to Additional Paid in Capital, Issuance Costs related to Common Stock, ATM and Registered Direct Financing	——	$940K+2.5%	$917K+7.6%	$852K-11.1%	$958K+143%
Adjustments To Additional Paid In Capital Share Repurchases For Payment Of Employee Taxes	——	——	——	——	——
Share-based compensation expense related to employee stock plans	$3.95M+16.2%	$3.4M-0.6%	$3.42M+1.2%	$3.38M+2.7%	$3.29M-2.1%
Pre-tax stock-based compensation cost	$3.95M+16.2%	$3.4M-0.6%	$3.42M+1.2%	$3.38M+2.7%	$3.29M-2.1%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Asset Acquisition Gain Loss On Acquisition Of Business	——	$0-100%	$611.75K-50.0%	$1.22M-33.3%	$1.84M-25.0%
Cash Acquired in Excess of Payments to Acquire Business	——	$0-100%	$302.5K-50.0%	$605K-33.3%	$907.5K-25.0%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Common Stock And Series A Preferred Stock Issued In Connection With Asset Acquisition	——	$0-100%	$6.45M-50.0%	$12.9M-33.3%	$19.36M-25.0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$106.93M-116%	-$49.59M+27.3%	-$68.2M-17.0%	-$58.28M+0.6%	-$58.62M-1.9%
Federal	——	$0—	$0—	$0—	$0—
Current State And Local Tax Expense Benefit	——	$0—	$0—	$0—	$0—
Federal	——	$0—	$0—	$0—	$0—
State	——	$0—	$0—	$0—	$0—
Depreciation	$53K0.0%	$53K+6.0%	$50K+35.1%	$37K+60.9%	$23K+130%
Effective tax rates	$0—	$0—	$0—	$0—	$0—
Effective Income Tax Rate Reconciliation Acquired In Process Research And Development Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Asset Acquisition Percent	——	——	——	——	——
Income taxes at U.S. statutory rate of 21%	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Fair Value Change Of Warrant Labilities Percent	——	——	——	——	——
Effective Income Tax Rate Reconciliation Fair Value Change Of Warrant Labilities Amount	——	$2.63M—	——	——	——
Other	——	-$0.01-167%	-$0-250%	$0-71.4%	$0.01-41.7%
Share-based compensation	——	——	——	——	——
Effective Income Tax Rate Reconciliation Research And Development Percent	——	——	——	——	——
State income taxes – net of federal income tax benefit	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	——	——	——	——	——
Federal Operating Loss Carryforwards Tax Effect	——	$0—	$0—	$0—	$0—
Financing Costs	$547K-59.1%	$1.34M0.0%	$1.34M0.0%	$1.34M-2.6%	$1.37M—
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	——	$4.59M—	——	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	——	——	——	——	——
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	——	$421K—	——	——	——
Share-based compensation	——	$264K—	——	——	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	——	$3.36M—	——	——	——
Income Taxes Paid, Net	$0—	$0—	$0—	$0—	$0—
Accounts payable	$1.88M+26,757%	$7K-99.1%	$742K+1,961%	$36K+109%	-$409K-286%
Increase (Decrease) in Accounts Receivable	——	——	——	——	——
Increase in accrued expenses and other liabilities	-$3.34M+4.6%	-$3.5M-1,204%	-$268K-111%	$2.43M-44.5%	$4.38M-25.0%
Increase (Decrease) in Contract Assets and Unbilled Receivables	——	——	——	$230K-52.2%	$481K-40.0%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Change in unpaid common stock issuance costs	——	——	——	——	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	$0—	$0—	$0—	$0—	$0—
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$57.15M+14.3%	$50.02M+93.0%	$25.91M+19.3%	$21.72M-2.8%	$22.36M+424%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$0—	$0-100%	$1.21M0.0%	$1.21M0.0%	$1.21M0.0%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$38.99M-10.6%	-$35.25M-7.3%	-$32.86M-3.2%	-$31.83M-10.3%	-$28.85M-12.8%
Non Cash Share Issuances	——	$57K+33.3%	$42.75K+50.0%	$28.5K+100%	$14.25K—
Other comprehensive income (loss)	$0—	$0—	$0—	$0—	$0—
Other income, net (Note 6)	$2.53M+27.2%	$1.99M-51.6%	$4.11M-0.8%	$4.14M-0.7%	$4.17M-6.7%
Proceeds From Issuance In Connection With Registered Direct Offering	——	$23M+33.3%	$17.25M+50.0%	$11.5M+100%	$5.75M—
Proceeds from Issuance of Common Stock	$7.65M+31.7%	$5.81M+3.2%	$5.63M+550%	$865K-64.4%	$2.43M-46.0%
Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement	——	——	——	——	$5.98M—
Proceeds from issuance of preferred stock	——	——	——	——	——
Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement	——	——	——	——	$15.52M—
Cash received from option exercises	$1.09M+208%	$352K+1,204%	$27K+440%	$5K0.0%	$5K—
Reclassification Of Warrant Liabilities To Equity Upon Exercise	——	$1.05M+33.3%	$789K+50.0%	$526K+100%	$263K—
Research and development expense	$33.44M+8.5%	$30.81M+12.4%	$27.42M-8.6%	$29.99M-0.2%	$30.06M+11.9%
Research And Development Expense Including Acquired In Process Cost	——	$0-100%	$7M-50.0%	$14M-33.3%	$21M-25.0%
Revenue From Contract With Customer Excluding Assessed Tax	$11.98M-15.6%	$14.2M-3.0%	$14.63M-5.1%	$15.42M+13.0%	$13.65M+24.2%
Stock-based compensation	$3.95M+16.2%	$3.4M-0.6%	$3.42M+1.2%	$3.38M+2.7%	$3.29M-2.1%
Expired (in dollars per share)	$4.480.0%	$4.48—	——	——	——
Exercised (in shares)	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period	——	——	——	——	——
Issued (in dollars per share)	——	——	——	——	——
Exercised (in dollars per share)	$0.950.0%	$0.95—	——	——	——
Exercised (in dollars per share)	——	——	——	——	——
Weighted average grant date fair value (in USD per share)	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value	——	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period	——	——	——	——	——
Share Repurchases for Payment of Employee Taxes	——	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage	——	——	——	——	——
Short Term Lease Cost	——	——	——	——	——
State And Local Operating Loss Carryforwards Tax Effect	——	$0—	$0—	$0—	$0—
Stock Issued During Period Shares Issued For Services	——	——	——	——	——
Issuance of common stock in connection with at-the-market program	——	——	——	——	$2.43M-46.0%
Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement	——	——	——	——	——
Stock Issued During Period Value Registered Direct Offering	——	$23M—	——	——	——
Stock Issued During Period, Value, Stock Options Exercised	——	——	——	——	——
Issuance of Series B preferred stock, (in shares)	——	——	——	——	——
Temporary Equity Stock Issued During Period Value New Issues	——	——	——	——	——
Unpaid Series B preferred stock issuance costs	——	——	——	——	——
Interest expense and penalties, net (benefit)/charge recognized	——	$0—	$0—	$0—	$0—
Utilized Federal Research Credit Carryforwards	——	$0—	$0—	$0—	$0—
Warrant financing costs	——	——	——	——	$1.37M—
EBIT	-$43.03M-11.5%	-$38.6M+40.8%	-$65.18M-0.5%	-$64.87M-0.9%	-$64.3M-3.6%
EBITDA	-$42.98M-11.5%	-$38.55M+40.8%	-$65.13M-0.4%	-$64.84M-0.9%	-$64.27M-3.6%
EBITDA	-$42.98M-11.5%	-$38.55M+40.8%	-$65.13M-0.4%	-$64.84M-0.9%	-$64.27M-3.6%
EBITDA margin	-358.7%-87.2pp	-271.5%+174pp	-445.1%-24.6pp	-420.4%+50.4pp	-470.8%+93.8pp
EBIT	-$43.03M-11.5%	-$38.6M+40.8%	-$65.18M-0.5%	-$64.87M-0.9%	-$64.3M-3.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Opus Genetics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's revenue?: Opus Genetics (IRD) generated $12.0M in revenue over the trailing twelve months, down 12.2% year over year.
Is Opus Genetics profitable?: Opus Genetics is not currently profitable: it reported a net loss of $106.9M over the trailing twelve months, a -892.4% net margin.
What is Opus Genetics's earnings per share?: Opus Genetics's diluted EPS over the trailing twelve months is $-1.33.
Where does Opus Genetics's income statement data come from?: Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.